0001096906-15-000294.txt : 20150327 0001096906-15-000294.hdr.sgml : 20150327 20150327141513 ACCESSION NUMBER: 0001096906-15-000294 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20141231 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20150327 DATE AS OF CHANGE: 20150327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DYNATRONICS CORP CENTRAL INDEX KEY: 0000720875 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 870398434 STATE OF INCORPORATION: UT FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-12697 FILM NUMBER: 15730395 BUSINESS ADDRESS: STREET 1: 7030 PARK CENTRE DRIVE STREET 2: BLDG D CITY: SALT LAKE CITY STATE: UT ZIP: 84121 BUSINESS PHONE: 8015687000 MAIL ADDRESS: STREET 1: 7030 PARK CENTER DR CITY: SALT LAKE CITY STATE: UT ZIP: 84121 FORMER COMPANY: FORMER CONFORMED NAME: DYNATRONICS LASER CORP DATE OF NAME CHANGE: 19920703 8-K 1 dynatronics.htm DYNATRONICS CORPORATION 8K 2014-12-31 dynatronics.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
Date of Report (Date of earliest event reported): March 23, 2015
 
DYNATRONICS CORPORATION
(Exact name of registrant as specified in its charter)
 
Utah
0-12697
87-0398434
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification Number)
     
 7030 Park Centre Dr., Salt Lake City, Utah   84121
 (Address of principal executive offices)   (Zip Code)
                                                                                                                                                                                                            
Registrant's telephone number, including area code: (801) 568-7000
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Company announced that Richard Linder has been appointed to the Company’s Board of Directors effective March 23, 2015, to fill the vacancy created by the death in November 2014 of board member Joseph Barton.  Mr. Linder began his career in the medical device industry in 1991 with Merit Medical Systems after attending Brigham Young University and the University of Utah.  In 1996, Mr. Linder co-founded Rubicon Medical, Inc. and served as its President and Chief Executive Officer, eventually taking Rubicon public.  In 2005, Boston Scientific acquired Rubicon Medical, and Mr. Linder worked for Boston Scientific until leaving in 2006 to become President/CEO and Director of Coherex Medical, a company dedicated to the minimally invasive treatment of structural heart disease.  Mr. Linder also serves as a Director of Vital Access Corporation.

He is a co-founder and Director of CoNextions, an orthopedics company, and serves as President/CEO.  Mr. Linder is a co-founder and Chairman of the Board of  BIO-Utah, and was instrumental in bringing together the life science industry in Utah.  He also founded the MD4 (Medical Devices, Diagnostics, and Drug Delivery) annual life science meeting for Utah.

Mr. Linder holds numerous U.S. and international issued patents and pending patent applications for medical technologies in the treatment of coronary artery disease, peripheral vascular interventions, neuro-interventional radiology, structural heart disease, heart failure, percutaneous ventricular assist devices, soft tissue tendon repair and tendon to bone fixation and tenodesis.

Mr. Linder will serve the remainder of Mr. Barton’s term, until the next annual meeting of the shareholders, when he will be included on the slate for re-election to the Board of Directors.

With the appointment of Mr. Linder to the Board of Directors, the Company regained compliance with Listing Rules 5605(b)(1) and 5605(c)(2) of the Nasdaq Stock Market.  On November 13, 2014, the Registrant received a notice from Nasdaq Listing Qualifications confirming that the Registrant no longer complied with Nasdaq’s independent director and audit committee requirements as set forth in Listing Rule 5605.  Due to the passing of Mr. Barton, the Board of Directors of the Company no longer had a majority of independent directors.  The Board of Directors has determined that Mr. Linder is independent under applicable rules of the Nasdaq Stock Market and that his appointment means that the Board of Directors of the Company now includes a majority of independent directors as required by Nasdaq.

Item 9.01 Financial Statements and Exhibits

A copy of the press release of the Company announcing the appointment of a new independent director to fill the vacancy created by the passing of its director, Joseph H. Barton, is furnished as an exhibit to this Current Report on Form 8-K.

99.1
Press Release dated March 27, 2015.
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
 
DYNATRONICS CORPORATION
   
 
By:  /s/ Kelvyn H. Cullimore, Jr.
 
Kelvyn H. Cullimore, Jr.
 
Chairman and President
 
 
 
 
Date:  March 27, 2015.

 


 

 EX-99.1 2 dynatronicsexh991.htm PRESS RELEASE DATED MARCH 27, 2015. dynatronicsexh991.htm
Exhibit 99.1
NEWS RELEASE
 
 
 
Contact: Bob Cardon, Dynatronics Corporation                                                                                                                                
           800-874-6251 or 801-568-7000

Dynatronics Announces Appointment of Richard J. Linder to Board of Directors

Salt Lake City, Utah (March 27, 2015) – Dynatronics Corporation (NASDAQ: DYNT) today announced that Richard J. Linder has been appointed to the Company’s Board of Directors effective March 23, 2015, to fill the vacancy created by the death in November 2014 of board member Joseph Barton.

“The addition of Rich Linder to our Board of Directors represents an important step forward for the company,” said Kelvyn Cullimore, Jr., chairman and president of Dynatronics.  “Rich is a proven leader and is well-known for his business acumen.  His breadth of experience and tremendous success working in the medical technology field will strengthen our strategic planning capabilities and help drive future success.”

Mr. Linder began his career in the medical device industry in 1991 with Merit Medical Systems after attending Brigham Young University and the University of Utah.  In 1996, Mr. Linder co-founded Rubicon Medical, Inc. and served as its President and Chief Executive Officer, eventually taking Rubicon public.  In 2005, Boston Scientific acquired Rubicon Medical, and Mr. Linder worked for Boston Scientific until leaving in 2006 to become President/CEO and Director of Coherex Medical, a company dedicated to the minimally invasive treatment of structural heart disease.  Mr. Linder also serves as a Director of Vital Access Corporation.

He is a co-founder and Director of CoNextions, an orthopedics company, and serves as President/CEO.  Mr. Linder is a co-founder and Chairman of the Board of  BIO-Utah, and was instrumental in bringing together the life science industry in Utah.  He also founded the MD4 (Medical Devices, Diagnostics, and Drug Delivery) annual life science meeting for Utah.

Mr. Linder holds numerous U.S. and international issued patents and pending patent applications for medical technologies in the treatment of coronary artery disease, peripheral vascular interventions, neuro-interventional radiology, structural heart disease, heart failure, percutaneous ventricular assist devices, soft tissue tendon repair and tendon to bone fixation and tenodesis.

Mr. Linder will serve the remainder of Mr. Barton’s term, until the next annual meeting of the shareholders, when he will be included on the slate for re-election to the Board of Directors.

With the appointment of Mr. Linder to the Board of Directors, the Company regained compliance with Listing Rules 5605(b)(1) and 5605(c)(2) of the Nasdaq Stock Market.  The Board of Directors has determined that Mr. Linder is independent under applicable rules of the Nasdaq Stock Market and that his appointment means that the Board of Directors of the Company now includes a majority of independent directors as required by Nasdaq.

About Dynatronics Corporation:
 
            Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.
 
 
 
 
 GRAPHIC 3 logo.jpg begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4` M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@`` M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`$4! M!@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/[^****`"BBFN2!QZT`.HJ'VEWKMG#,B>'8-2LM0L[?\R+?_@O1_P`%9/`VNZAI7BSXTZ7J M&KZ/>2V.K>&?'WP%^$^C7FFWMN2L]CJ5AX?\#^#-9LKF%P5D@GEAE4@Y`K]6 MRKZ/'%^<_7:>7Y]P;5QV6U?89CE4\RS:AFN`K]*>,P5;(H5,/[2_-1J5&J&( MIM5+*6!S"DJ^`S:&7Y97RO&47]O#8NCG-2- M;D?NU:<(NK0FG3K4Z=2,HK_0^HK^*+X$_P#!T!\?-"U&PLOVCO@%\.?B#X>\ MQ(M0USX57FL^`_%D,)VK)=Q:3XAU+Q1X=U*91EQ:"XT*.1LI]IB4@K_5'^Q[ M^VY^SY^W+\-!\3/@#XQ_MRTL)XM/\6>%=7MAI/C;P+K,L9E32?%GA^1Y);*6 M>-7EL-0M9+O1]5A1Y=,U"Z6*7R_B>,O"KCC@2DL5G^3RAETIJG'-,%6I8[+^ M>3M&-6M0DYX64W[M-8NEAW5EI34FFE]APEXF\&<:U'A\BS:%3'1@ZDLNQ=*I MA,=R12O\`+_"@":BH=S>O\O\`"CO\O\`"@":BH=S>O\`+_"CO\`+_"@":BH=S>O\O\`"CNZE<,$M[#1]$L9]2U.\G=B%6*WL[::5B2 M.%K_`"U/VQ_VB];_`&LOVG?C/^T#KDD^?B)XUU/4-"LIY'D.D>#[%UTKP=HT M>_[D>F^&[+3;=D``\Y9G(W.Q/]HW_!Q;^V?H?[,W[$G_``J.#Q-;:%X]_:HU MR7X>:?&9VCO8OAWHL=OK/Q*U*,1;I4@N;-](\)22;5#+XHD",3$XK_/Q_P"% M@>"1P/$VEX'I)+_\9K^Q?HRT.&,AP.=\49YG^09=F68U8Y3E^&Q^<9=@\71R M["N%?%5G0KXFG6C#&XMT8)SA&ZP*E&\9W?\`)GTC:G$V>8O)N&\ER'/LQR[` MTY9ICL3@,HS'%X:ICJ_-1PU%5L/AZE*4\+AE5G)1D[/&(-1MK;4WN8-PADOO#< M\D7B31+AU\VUO]/\N-A!=W22?W%_\%"O^"4?[-O_``4+\)7/B"ZT_3OA[\//%GA[P=X9TFQ6XN+S4==\1ZK::3I=G;P MQP,[R37=W$O`X7#/"7ANZD6:Y\/^&/#^A7,R_=FGTC2 M+/3YI%/4J\EN[*<]#7/](/B+*LLXEX/XPX%XCP*XB5#,,+C\7D&987%2^KX* M6"E@5COJ=6K2G":Q&*H.CBE*&*P\?8SA.C148]'@/D&:8_ASBKA3C;A_'+(? M;X+$8'"9[E^+PJ]MBX8J&-^I?6Z5*K"4/8X>JJN&E&5"K/VD)0J56Y?Y7W[2 MG[-_Q8_9-^,OC#X%?&CP^V@>./!]TB2F%GGTC7]'NP\NC>*?#5^Z1C4_#NNV MB_:M/O4164B>SNHK>^M+JVA^Y?\`@BS^T/XO^`'_``4*^!,6A:I>0>&?C%XE ML_@[\0-$CGD6PUS0_%Q>TTF6[M=PAFNM!\1-INK:;,RF6W>*XCC98[JX63]F M_P#@ZIT;X3>'O"?[)'Q+UC4-'T3XH7_B?Q]X#M))BB:CKO@&UT:R\0W4U.VU/_ M`(1#Q==?%?7%M?-CEV M,JX:E@\57P]6=+%8VE0>%_V6E5JX;&3E.,)TX5)5(0A-P7]]O[9W_!0+]FS] M@?1/`VM_M$^(?$.DP_$75M6T?PM8^%O#-_XJU2\FT.TAO=5NIK*P(>VT^SCN MK.*2[E8(;B[MX4#,YQ\#P?\`!Q9_P3)GG2%_''Q7M0SHKS7'P?\`%!B@#]&E M%L)Y@HZG9$YP#A2:_F[_`.#BK]K?P[\8O^"@DOP3TGQ-97=A^SEX8T+X96^C MVTTL[3?$GQB;3Q1XJACACCD1M1\S5?#?AJ1$_>K=:2\##>NT?('_``5"F^#O MP'^)GP/_`&0?"MKX.T?QA^S-^S[\.?"/QEU71]+M+;Q)XR^//Q!T^'XC^./^ M$CU*PM/MFN7FBR^)M)\/Z4E_-/#G#4JN2Y'B,#@\O>)XTV_N+9;?4]0.F6]K&85>-$DE0G#CZF^*7_!4 MC]M/XV_\%5]`_P"">?[''QR\,6&E^#]6\._"KXG>(U^'/A'Q1=7/B7P'IL-] M^T'\2)I]2TF[BL+3P_.FL:7:Z=:20:<-3TNWMH8UEOE2OS3%^&M"MC9U9\+\53S7#RR7!8Z&79%7J8*OF>:85U<0\MJUJZ53+ M\#6IU:6+QE:I"AAI>SA.M-SC)_UN45_$[XT_X+2?MW?'G_@HG\2_V"_"MWX=M_!?P1T74;WQ]XS\9^+I]$N=3AT"Z@\(^ M(=?U&^MID,%K>P6FFF$FW->J?\$:_P#@L?\`M>?M>_M=>-?"7QN^+_@CQO\` M`_PK\&?B1\6OB`^F^!/#WAJT\!Z/X32Q;3M MKG*<<##"1P_ MLZF91Y*E.>%A7DXU8.#G[T'+:AXB87$9Q2RB/"W&]/VV:5*E6YH8"3G"4,5.E&,J(^$Q>8+`4^%>. M8PJ2QL:.85N&J]#`UG@:4ZTVIU:T*]*.(C%1PDL1AZ*KU)P@K-RY?W)\>_\` M!7W]C#X>_M0-^Q_J>O?$36?CUDU6VBU:8?NM-D2Z6X93:R[?U`K_.,_X)4_#O]J#]OC]N/7/CU\#_`(G^ M!;;XK_#/Q+;?''XG_%3Q[I,>J:=IMWX\U^ZTO4;S3=!?1-1TFZ\57MK?>(K[ MPWIL]O;:?8/I?GQSV@L[=E^__$'_``6O_;T_:"_;X^+'P-_8X^-_PML/AWX: M\4_%.\\)6/C3P1X5N/#NG?#3X&:'JNK>,?%OB_Q7-HMUJL>D7>G^%-5U>ZNH MK@,'U2TL+"2$R6S#Z[BGPJX8AC\OROA/C?A.=3!<.+,.),?G'%&&C@I9G"5" M%2AET\-@94W&NIU*^%P\*N)Q'LX5HXA494Z/UGY?AKQ)XDJ8+'9CQ1P=Q/3A MBL^E@K2PM%3E3E1=:$ZCH?VZ45 M_%O_`,$W?^"\7[3GCRY_;%^+?[2GQ'\&_$_X(?L\_LUZ_P#&+4K+2_!VA>#V MTGQK<^+/#OAGX:>'-)UC1-.LIDM?&>K:K=Z*EGJ9U*YV1_;8/WMI()/EJ7_@ MM_\`\%._BK\%_C?^UCH7[1/P@^%WP?\`A'X_^'?@"YT'2_AQX8=-0\8?%6;5 M[GP[X)\(3:_X?\0:EKM]HN@Z'J.O:]<:GJT4D&DPIGF-3BN@\!B:V8N,:=#"3I8>IB*TZ$IP6,J?5H4,-SQE.MRJ M;C]'/Q,PD<#A<;#A+CVK4Q3QS6`APQB%C*M8T_0);^74?#L,0T/6IO")NM;O/-@TZ&WNDTZ>VO896 MM9I7_.'4O^"W_P#P50TG]E[1/VDM7_:*^$>G_#?XD_%[7?@UX(U>?X9>"H?& MNI>)O`'AVS\3>,KSPYI*^'AITOAG3HM8-9=FL*J%*CCZDJ.'K_6\NG##U'B,"H8A0>(G&E' MVU.M1MSTY(TQGB1A,)1P%9<*<=8MX_+I9DJ6$X9Q%6MA(*M5H?5L="56"H8U MSIRG3J-*,TS^]GQIXP\/?#WP?XJ\>>+M1AT?PKX+\.ZSXJ\2:K<' M$.G:'H&G7&J:I>/DC(M[*UFD"`[G90BY9@*^`OV-O^"K/[)'[>/C_P`0_#C] MG75/B'KVO^%?"K>,=?GU_P"'^J^'-$T[1?[2L])@,^K7DA@6\O;R]C2RLR#- M/\`5_AU M\//$&J^!]`N?#WBCP=IGBCQ`VH>)-3\!:A87/AK4A/X.\-7EA=QR:5_9-U)J M-C>M:(9U5O*?A#_P5;^*W[+O_!*+4/VX_B.GP2U/XP?M)?&G4OA/^S5!HWP? M\#_"[P^OAOPC:WEOKOBO7;+X=Z%X:O/&&G:9J^E>*;F"TO)S#]LMM*B2X@M[ MRY9]\%P'E\,ESMXW,L@Q>=+B2GPSDE3#<9X#"8;VT*\:6(S:I@ZN75?KF1N+ MJ589G5S#+*,*=".Q-9T9TG4 MHY9#%4\93^K9TI1A2GEU/!XZLYU8Q;II2E'^Q6BO\_GXB_\`!:O_`(*E_#_X M-_`G]H[Q3^U5\,=(\*_M&WWQ+E^&OA*U^%W@-=3NO#WPNUZR\,Z[XKO--N/" M3>1X9O?$=S>:+HMR-4FGO;C1]0+*J(LC?I;^U_\`\%X?CG^S7^PG^Q#KMS-\ M-M*_:Y_:G^$]Q\7_`!'KVK>'Y)/#OAGX:1ZQP$&K2I9S+]G@BY\=X5X[!U,/#[,99GF57+.;`\4X?V6`JT*. M)K5L3F%3%T,)&A@:<<+5@L5'VL:U5T:6'56>(H*IK@_$G!XJGF56IPKQU@5E MV!I8_DQG#&*53&TZU3#TJ6'P%/#U,0Z^,G+$TY/#/V$O@IX_T'X0I\,_!LS6 MMM\>+JUF^'O@CQ5;V/AK2=6TSQ%KNE7VCWUU;:7J7VC3M/UVTD6\CN5&/4)7FFFT+ MPEI?BWQA(D4Z6+IW@N;RZM+&RM;F^O[^Z@L;"PL;>:\OK^^NI!#:V5C96R2W5Y>74S+#; M6MM%+<3RLL<4;NP%?;/PK_8P\2?$*[3QA^T=^T)\`?V0?`>KWW_@A7XO\`@;XA\._MW_MG^%7\/_%&UL7NOV?/@AK4"-J_P[35 M;22"7XF_$.T;>EAXYN=.N);7PKX7?==>$K6YN=3U?RO$$UK:Z/\`T$?MZ?\` M!4C]CG_@G3X-N=<_:`^)NGGQQ%+>X$ MVD:;/(\:R^)?$LFC^';2/>\NHM(JP/\`P=_M9?\`!S?_`,%&?VF(M2\-?#+Q M7X,_95\#ZGOMQIWP3MWU/XA7-JZM&([CXF>)/MVL6ERZ,1)+X6TSP[(6YB=2 M%Q^1?PY_9P_;!_:U\:7E[\-O@G^T/^T#XY\57SW.I^*+7P?XX\77NJWDTA\R M\UWQSKENUCA7+-+=ZKKB0PC=F1%`6C;9&?LW)J4VHK^6^R[+MYGO/_!2[_@H M]\8O^"FG[1-Y\%/"N@V$WA?X1?"O3[U[W1_AKX&%X]X;1[UDB76/% M.N7&S4O%WB(P6XU"^2WL[2WM-(TO3;2#^I/_`(-N_P!DBW_8U_9+_:*_X*K? MM!Z4WAQ/%GPQ\17/PNMM8A-GJ%E\!?A_:77BKQ#XP6.YC62V_P"%G^(]*M+? MP^,QRWN@^'].U"(/:Z];EO(_^"7G_!K?XSE\4>%_C3_P4FGT;2?#&C75GK6D M?LN>%=8BUS4?$MU`8KJSA^+OB_2W;2K'0EDV?;_!WA>[U"ZU-4ELM3UNR@\V MUG_>#_@NYX!_:8\<_P#!.;Q)^S;^Q;\$/$_Q*\4_%G7?!?PUU7PY\.;;0],M M/!GP@T61=:UT"&^U#1["PTJYM=`TOPE96%DV!;:D\$<*P1-@MY?@*4X^[3C: MVB;\M-+_`)L_A3_X)S:=_P`-F?\`!4B#]H3XZ$7O@OPAXQ^+'[>7[0U[J`\R MTA\(_"Q]5^+%Y87CRD(+>]\1KX<\,6D4K*CI/';J.@KH_P#@G'X!\2_\%1/^ M"S/@+Q5X]L9=6MOB+^T!XJ_:D^+23@S6]MX1\*ZW=?$1]'N"X<+8O>1>&O!M MO$_[L6]S!;*N-JUZA\#/^";_`/P6J^`_PP_:5^%?@#_@GUXYAD_:K^'VA_"/ MQOX[U:?PFOBGPY\.[#Q%#XDUWPWX3N5\=6^FZ?!XWN[33[+Q1>7]O_X)^V_Q<_:2_:TTCP_X.^-'Q(\/V/@;PCX&M=> MTGQ!'E@DD*W)G^-6M:2UY$@+BTM]1F=%2!ROU MK_P2@\!ZC^PO_P`$N/V\/^"ROQ::1_C7\:_!GC/P#^SMJ^MAO[7N9?$VOS:" MWC.UDN!YTEY\0/C)JL>H/<12>;/HO@Q[H%[6^);\-+3X1^-O^"H/_!5[QU\/ M/!$TT^I?M-_M:_%+5[O7[=&N8O#/PZN/'FO:MXC\92.AE5;7PYX"M9KVWDW& M*:YCLK9'+74:M_8)_P`'`W[)'[5'C[]D7]D;]A/]@/\`9G\=_$+X/>`[ZRU/ MQ@G@<^'[;2O#_A_X4^&;7PK\-/#%^VJ:QI#7=]?7&IZCKURR0S>=7$G MVB;<3^OZ^X4O^7<+[I7OM;T^]>BL?R8_L8/-\`OV%?\`@H)^V)>S21>+_B%X M=\-_L%_!;5I9'6_F\4_'=V\6?';7=/E+B:2ZTGX1^')["[NXG+Q2^*U61AYS M!OU9_P""1'Q,^#O_``3%_P""5G[4W_!0GX\?"Y/BU>_M3_$>R_9;^$/PCNI+ M"Q@^)?ASP[I>JCQ!I&JWFHVU];VO@;4-5O?$\OBV\&GZFDFG^$A8QV%W./VAOCUJ.CR^$XM/C M_:.^.FN&"3PGJ$UWXDM3>7_PQ^'/AWPSX:NYX5N;2"ZN[Z*VN9DW&OMK_@L% M_P`$H?VY)_V3_P#@F)^RI^RC\"_$7QA^&7[.'P?UV#XE0>!]0\/?VA:_'KQ0 MFAS^)]=UC3=3U;2I9["_NY?$%SI^K0K<0Q/?7T$S0[H]X.3B[*ZM*2;75122 M2\KVOZ/0_$[]KW]KG]IOXD?LOZ7\0_#_`,`OV0OV*?V4OVM?$OB'X%M,@.T;'MOB-(K<7#"3S3XV?\$K/^"O/[1^I?LA?`OQ+^PGXI^%7P MQ_9]^%_@']G[1-2T#Q3X5\1>$M+L/$?BF3Q+\2?B_P"(=47Q)O;6]7QN^(/[)G@7]D?]GO7OBK M^S%^SK^S;H_PK\$V_@C6_"\>H:#XGM;O^S][]K?]N>_BCTCXJ_M+IXC7X97%RGDWLXNY3\%?@Q'9,0)I(X_$FJ^(_&J(NU M&L6DN<%4S7@G_!L'_P`$]_"'[3?A7]N7XL?&2S\03>`/%_PZ'[(^G7^AZUJ' MASQ!>V?C];3Q7\8WTCQ'8%-0TV[N]"M/"6@WM[93+.UEK>JVF]?/E(]\_P"" MD_[.W_!3_P#:*_X)=?\`!.+]DGX=?L&>,O"U[X'TNZ\1_&;X:_#S6]$U73/! MB?"[3I/AY\(-`\17^M:WIIN?%'B"PN]<^(&NV-FU_8V-Y>Z>GVR69-Y_HU_X M(S_L=ZQ^P[_P3P^`GP5\8Z&?#_Q0O-)U#XC?%W3)#;O=V7Q%\?7KZWJVEWTU MK)-!-=>';!]+\-2/%/-%_P`2?$4C1A20AR2C)W]Z4]]'HMO+[EUU/Y7/^"]/ M[-7[(?\`P2E_96\*_L>_L?>'?$'A36OVS_B7H7Q0^-I1V-N4MKJ[T"\GF5VB79^-O[9*2?`+]A'_@ MG_\`L=V43Q>,?B)I'BK]OKXWZ5#%LO9O%'QR9?!7P!T#4HP!,]YHGPA\./?V M]M(NZ)O&"R(N903^Y'_!PA_P3F_X*4_M7_\`!0EOBS\+_P!F;Q?\=/@)H/PS M^''A'X=W'@K7/#4T<6FZ5]IUGQOH>K:9>:[I^KZ/?ZEXIU36!)/]F'X!>'?&OP\\5:[X/\ M2^)="U".S\"?!S2="TSX<_!;P)H=CJFIZUJ-@UIX9T72+[5=3M=.L;>Q.J7L MGFWD\-I,%1DDHMR3^*3U]Z^B2[O_`"7D?$G_``62'_#+G[*7_!,?_@E]H.P^ M(OA1\&&_:4^/.EZ<7\Z^^-WQSGN6TK3-2MQD3:GI2W/C%+9'0R?9M8TUDPKQ MU\Y_\%"/`6N_\+4_80_X)=_#R-[K7_V<_A#\,?A=XATZS42)>?M4_M3:WIWQ M,^+UY+'$/WE[H^H>+?"GA:Y=@TMM!X9E@%I+34?A)\!M/DN/ACX)M+.W\0W- MTUYX]M_!GAW1;.S:VCB^U^(YFNC`HE<=-_P2T_X)B_MX^-/^"N.L_MS_`+_:52X\42>&[G_A(/BGKEW=Q^`_".C6VF:]J4TM[HLGB` MZC8))'#;1IX;MHA/&3&*`4DDM;-1DW9K64FM=.W_``VF_P`8_P#!PIKL"_M& M?L<_\$P_@@HU'PU^QK\"/AA\(M'T33\-%J7QE^*MKH%D&:&+(.H/X>L?!+S% M@\JW>O:D'^>205S'_!=.)M"^,7[#'_!*?X,*=5L_V-?@'\+?A5_9&F2+394RI=>(M0#;2[+7W;^PC_P3"_;W^/?_!:C M_AM/]M7]F;QY\*?A='\8OB+^TA>:QXYE\,SZ?/K6E7-S_P`*B\%6]MINO:I< MR2Z9<3>&I(H6MA;06'AN4,1B-6^;/B/^P-_P6"^''_!5;X@?MQ:C^P+XG_:( MUO2OVC_'GQ>\%KI_B;PO>_#W7[C[;K$7PHU9-2LO$`U&/2_"%J?"VK6>D7=E M9S!]!M]+NQ;?O)$/*V@XM)Q2DM(-[_:E;ON?HWK_`,(/^"`/[0?QO_9I_P"" M>'Q=\3?'OXB?M/?L[>#O"/[#N@^&_ATOQAT/P`OBOP3-J5WXW-MJ>@:9'X2( MO_&E[XJUKQ;XJ^V&V>9+A[J],5BK#Q+_`(+/?\$X/AY^W'^T#IOC7]AG]MW] MD[XA>-OAA\%=&^"EI^Q=JGQB\):7XWT'0?@#I.NC4M*^&%]9ZMJ%G-<:;I5I MJE[K_A[Q-9Z(+"\T^^N3KBH3;P=5_P`$9/\`@C/^WM\)/C7\<_V[OVE_A_:? M#_XS:9\+?C2_[/'@SQAXD\/:GXL\4_M!?%'1=9B'CCQ(-*OM7T_PMI.G7.HW MMK!/J=\-0N+W7FNA!#:V,DS_`)+?L\?\$UO^"R'[+WB_XY>)=&_X)W_$;Q5\ M3_BU\%?BC\$[+XA3:UX.D/P_N?B[]GTSQW\0?#6I:?XI>UU;Q!J'AUM?T*RG MN;F"".'Q%Z=IFO6%OX=\6Z6-'U>QFT2U22*_2875K_<57\P7_!N1_P24^,G[`/A M'XQ?&_\`:@\-Z;X-^-_QGM=!\&^'?`EMK&F:_J?@;X8>'9VUB>/7]3T:>\TJ M/6O%GB&6TO+C2[&]NUL++P_I@NIS=320V_\`3[095&G)VVTMK?HM@HHHH("B MBB@`HHHH`*Y[Q)X1\*>,K.VT[QAX8\/>*]/L[U-2M+'Q)HNFZ[9VNHQVUU9I M?VUMJEM=0P7J6=]>VB742+.MM>74`D$5Q*K]#10!XHVME:6,"6MC;P6=M%D1V]I#%;01@G)"10HD:`DY(51D\U M:HH%<9Y8]_T_PHV#U/\`G\*?10`W;[M^?_UJ_&[]O;_@B7^SY_P41^,MM\:? MC+^T+^V1X*U.Q\#Z3\/]/\%?!KXJ^!/!WP[L="TN[U2_DECT'6?A+XLO[C4M M7O-7NY]8N]0UF\2YQ!!#!;6T*PU^R=%`TVG=:,_*+_@GG_P1D_8F_P"":6L^ M)O&7P$T#QQXG^)WBO2/^$=U+XJ_%[Q-I_B[QM;>&FN8[R?P]H7]B^'O"GA?P MYIE[=06TVI?V'X9L+W4S:VT>H7ES#!'&OZM[,="P_'_ZU.HH!MMW;NQNWW;\ M_P#ZU)L'7)S_`)]J?10(;L]V_/\`^M2;!ZG_`#^%/HH`;L]V_/\`^M2;![_Y M_"GT4`,"`="1]#_]:@H#U)/UY_I3Z*`&;!TR_\`G\*4)CH6'T/_`-:G44`,V`]_Z?X4^BB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`" BBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__V3\_ ` end